

Jinoos Yazdany

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4075348/jinoos-yazdany-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

5,740⁰
citations

32
h-index

72
g-index

180
ext. papers

7,928
ext. citations

5.8
avg, IF

6.3
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 152 | American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care and Research</i> , 2012 , 64, 797-808 | 4.7 | 863 |
| 151 | Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 859-866 | 2.4 | 575 |
| 150 | Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. <i>Arthritis Care and Research</i> , 2012 , 64, 640-7 | 4.7 | 440 |
| 149 | Potential Biases in Machine Learning Algorithms Using Electronic Health Record Data. <i>JAMA Internal Medicine</i> , 2018 , 178, 1544-1547 | 11.5 | 359 |
| 148 | Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 930-942 | 2.4 | 210 |
| 147 | Depression, medication adherence, and service utilization in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 240-6 | | 136 |
| 146 | 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2020 , 72, 529-556 | 9.5 | 135 |
| 145 | Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , 2020 , 2, e250-e253 | 14.2 | 125 |
| 144 | Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 143 | 5.7 | 112 |
| 143 | A quality indicator set for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 370-7 | | 107 |
| 142 | Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 480-6 | 27.4 | 101 |
| 141 | Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. <i>Arthritis and Rheumatism</i> , 2008 , 59, 136-43 | | 91 |
| 140 | Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011 , 63, 1170-7 | 4.7 | 69 |
| 139 | Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2019 , 2, e190606 | 10.4 | 67 |
| 138 | Choosing wisely: the American College of Rheumatology® Top 5 list of things physicians and patients should question. <i>Arthritis Care and Research</i> , 2013 , 65, 329-39 | 4.7 | 65 |
| 137 | The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 293-294 | 8.1 | 64 |
| 136 | The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008 , 35, 1782-8 | 4.1 | 57 |

| | | | |
|-----|--|-----|----|
| 135 | Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1386-1388 | 2.4 | 56 |
| 134 | 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis Care and Research</i> , 2020 , 72, 461-488 | 4.7 | 54 |
| 133 | Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?. <i>Arthritis Care and Research</i> , 2011 , 63, 358-65 | 4.7 | 51 |
| 132 | Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1137-1146 | 2.4 | 49 |
| 131 | Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Mulhearn. <i>Annals of the Rheumatic Diseases</i> , 2021 , | 2.4 | 46 |
| 130 | Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R84 | 5.7 | 45 |
| 129 | Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 57, 593-600 | | 45 |
| 128 | Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016 , 68, 1866-1873 | 4.7 | 44 |
| 127 | Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. <i>Rheumatology International</i> , 2017 , 37, 1249-1255 | 3.6 | 42 |
| 126 | Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1474-80 | 9.5 | 38 |
| 125 | Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011 , 63, 542-9 | 4.7 | 37 |
| 124 | Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2828-36 | 9.5 | 36 |
| 123 | Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021 , 7, | 5.9 | 36 |
| 122 | Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. <i>Arthritis Care and Research</i> , 2010 , 62, 993-1001 | 4.7 | 34 |
| 121 | Defining quality of care in rheumatology: the American College of Rheumatology white paper on quality measurement. <i>Arthritis Care and Research</i> , 2011 , 63, 2-9 | 4.7 | 32 |
| 120 | Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 434-440 | 5.3 | 32 |
| 119 | Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL). <i>Arthritis Care and Research</i> , 2011 , 63 Suppl 11, S413-9 | 4.7 | 31 |
| 118 | Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. <i>Arthritis Care and Research</i> , 2020 , 72, 622-629 | 4.7 | 31 |

| | | | |
|-----|---|-----|----|
| 117 | Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. <i>BMJ Quality and Safety</i> , 2014 , 23, 659-66 | 5.4 | 30 |
| 116 | Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. <i>Arthritis Care and Research</i> , 2014 , 66, 617-24 | 4.7 | 30 |
| 115 | Development of the American College of Rheumatology@ Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016 , 68, 1579-1590 | 4.7 | 30 |
| 114 | Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care. <i>Journal of General Internal Medicine</i> , 2012 , 27, 1326-33 | 4 | 29 |
| 113 | Quality measurement and improvement in rheumatology: rheumatoid arthritis as a case study. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3649-60 | | 29 |
| 112 | Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 386-92 | 4.7 | 29 |
| 111 | National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. <i>PLoS ONE</i> , 2016 , 11, e0144918 | 3.7 | 29 |
| 110 | Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021 , 73, 374-380 ⁵ | | 29 |
| 109 | Efficiency Gains for Rheumatology Consultation Using a Novel Electronic Referral System in a Safety-Net Health Setting. <i>Arthritis Care and Research</i> , 2015 , 67, 1158-63 | 4.7 | 27 |
| 108 | Relationship Between Poverty and Mortality in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 1101-1106 | 4.7 | 25 |
| 107 | Health-related quality of life and employment among persons with systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010 , 36, 15-32, vii | 2.4 | 25 |
| 106 | A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1612-1622 | 9.5 | 24 |
| 105 | Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators. <i>Seminars in Arthritis and Rheumatism</i> , 2010 , 40, 193-200 | 5.3 | 23 |
| 104 | Quality of care in the rheumatic diseases: current status and future directions. <i>Current Opinion in Rheumatology</i> , 2008 , 20, 159-66 | 5.3 | 23 |
| 103 | Validity and Responsiveness of a 10-Item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population. <i>Arthritis Care and Research</i> , 2017 , 69, 338-346 | 4.7 | 22 |
| 102 | American College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology. <i>Arthritis Care and Research</i> , 2016 , 68, 1390-401 | 4.7 | 21 |
| 101 | Automated and flexible identification of complex disease: building a model for systemic lupus erythematosus using noisy labeling. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019 , 26, 61-65 | 8.6 | 21 |
| 100 | "Am I OK?" using human centered design to empower rheumatoid arthritis patients through patient reported outcomes. <i>Patient Education and Counseling</i> , 2019 , 102, 503-510 | 3.1 | 21 |

| | | | |
|----|--|------|----|
| 99 | 2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019 , 71, 1531-1539 | 4.7 | 20 |
| 98 | Patient-reported outcome measures for use in clinical trials of SLE: a review. <i>Lupus Science and Medicine</i> , 2018 , 5, e000279 | 4.6 | 20 |
| 97 | Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 267-272 | 5.3 | 18 |
| 96 | Post-marketing experiences with belimumab in the treatment of SLE patients. <i>Rheumatic Disease Clinics of North America</i> , 2014 , 40, 507-17, viii | 2.4 | 18 |
| 95 | Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 931-933 | 27.4 | 18 |
| 94 | Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2020 , 2, 53-60 | 3.5 | 17 |
| 93 | Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2129639 | 10.4 | 17 |
| 92 | The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , 2021 , 60, 353-358 | 3.9 | 17 |
| 91 | Does Systemic Lupus Erythematosus Care Provided in a Lupus Clinic Result in Higher Quality of Care Than That Provided in a General Rheumatology Clinic?. <i>Arthritis Care and Research</i> , 2018 , 70, 1771-1777 | 4.7 | 16 |
| 90 | Relationship Between Process of Care and a Subsequent Increase in Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017 , 69, 927-932 | 4.7 | 16 |
| 89 | Systematic review of the literature informing the systemic lupus erythematosus indicators project: reproductive health care quality indicators. <i>Arthritis Care and Research</i> , 2011 , 63, 17-30 | 4.7 | 16 |
| 88 | Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 525-533 | 4.7 | 16 |
| 87 | Medicare Part D Plans Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. <i>JAMA Internal Medicine</i> , 2017 , 177, 585-588 | 11.5 | 15 |
| 86 | A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. <i>Nature Communications</i> , 2019 , 10, 3902 | 17.4 | 15 |
| 85 | Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1087-1092 | 5.3 | 15 |
| 84 | Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. <i>PLoS Medicine</i> , 2019 , 16, e1002800 | 11.6 | 13 |
| 83 | Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. <i>Journal of Rheumatology</i> , 2015 , 42, 1616-23 | 4.1 | 13 |
| 82 | Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018 , 37, 467-474 | 3.9 | 13 |

| | | | |
|----|---|------|----|
| 81 | Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review. <i>JAMA Network Open</i> , 2019 , 2, e1914745 | 10.4 | 13 |
| 80 | Factors associated with access to rheumatologists for Medicare patients. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 511-8 | 5.3 | 12 |
| 79 | Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 1447-55 | 4.7 | 12 |
| 78 | Leveraging the electronic health record to improve quality and safety in rheumatology. <i>Rheumatology International</i> , 2017 , 37, 1603-1610 | 3.6 | 12 |
| 77 | Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. <i>RMD Open</i> , 2020 , 6, | 5.9 | 12 |
| 76 | Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study. <i>BMC Health Services Research</i> , 2016 , 16, 499 | 2.9 | 12 |
| 75 | Using Health Information Technology to Support Use of Patient-Reported Outcomes in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 257-273 | 2.4 | 11 |
| 74 | Interactions between patients, providers, and health systems and technical quality of care. <i>Arthritis Care and Research</i> , 2015 , 67, 417-24 | 4.7 | 11 |
| 73 | Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries. <i>Arthritis Care and Research</i> , 2015 , 67, 1210-1218 | 4.7 | 11 |
| 72 | Using Medicare data to understand low-value health care: the case of intra-articular hyaluronic acid injections. <i>JAMA Internal Medicine</i> , 2014 , 174, 1702-4 | 11.5 | 11 |
| 71 | Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e855-e864 | 14.2 | 11 |
| 70 | Psychometric Evaluation of the National Institutes of Health Patient-Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 1630-1639 | 4.7 | 11 |
| 69 | Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2021 , 3, e707-e714 | 14.2 | 11 |
| 68 | Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study. <i>JMIR Medical Informatics</i> , 2018 , 6, e31 | 3.6 | 10 |
| 67 | Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes. <i>Npj Digital Medicine</i> , 2020 , 3, 57 | 15.7 | 10 |
| 66 | Type I interferon, anti-interferon antibodies, and COVID-19. <i>Lancet Rheumatology, The</i> , 2021 , 3, e246-e247.2 | 14.2 | 10 |
| 65 | Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1004-1006 | 2.4 | 10 |
| 64 | Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates. <i>Journal of Rheumatology</i> , 2019 , 46, 370-375 | 4.1 | 10 |

| | | | |
|----|---|------|----|
| 63 | Major Depression and Adverse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort. <i>Arthritis Care and Research</i> , 2021 , 73, 48-54 | 4.7 | 10 |
| 62 | Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus.. <i>Science</i> , 2022 , 376, eabf1970 | 33.3 | 10 |
| 61 | COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.. <i>Nature Reviews Rheumatology</i> , 2022 , | 8.1 | 9 |
| 60 | Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab. <i>Medicine (United States)</i> , 2017 , 96, e6528 | 1.8 | 8 |
| 59 | Patient and clinician perspectives on a patient-facing dashboard that visualizes patient reported outcomes in rheumatoid arthritis. <i>Health Expectations</i> , 2020 , 23, 846-859 | 3.7 | 8 |
| 58 | Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis. <i>Pediatric Rheumatology</i> , 2018 , 16, 30 | 3.5 | 8 |
| 57 | Methods for Developing the American College of Rheumatology® Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016 , 68, 1402-9 | 4.7 | 8 |
| 56 | Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 111-116 | 5.3 | 8 |
| 55 | RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1542-1548 | 5.3 | 7 |
| 54 | Challenges and Opportunities in Using Patient-reported Outcomes in Quality Measurement in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 363-75 | 2.4 | 7 |
| 53 | Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making. <i>Arthritis Research and Therapy</i> , 2015 , 17, 367 | 5.7 | 7 |
| 52 | Healthcare quality in systemic lupus erythematosus: using Donabedian® conceptual framework to understand what we know. <i>International Journal of Clinical Rheumatology</i> , 2012 , 7, 95-107 | 1.5 | 7 |
| 51 | Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic. <i>BMC Health Services Research</i> , 2016 , 16, 384 | 2.9 | 7 |
| 50 | Response to: Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis by Gyöfi. <i>Annals of the Rheumatic Diseases</i> , 2020 , | 2.4 | 7 |
| 49 | Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. <i>Rheumatology International</i> , 2017 , 37, 1611-1618 | 3.6 | 6 |
| 48 | Influence of Continuing Medical Education on Rheumatologists' Performance on National Quality Measures for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2015 , 2, 141-151 | 4.4 | 6 |
| 47 | COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco . Compassionate use of | 2.4 | 6 |
| 46 | Increased Risk of Ischemic Stroke in Systemic Sclerosis: A National Cohort Study of US Veterans. <i>Journal of Rheumatology</i> , 2020 , 47, 82-88 by Khan. <i>Annals of the Rheumatic Diseases</i> , 2020 , | 4.1 | 6 |

| | | | |
|----|--|------|---|
| 45 | Impact of Limited Health Literacy on Patient-Reported Outcomes in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2021 , 73, 110-119 | 4.7 | 6 |
| 44 | Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. <i>Arthritis Care and Research</i> , 2021 , 73, 146-157 | 4.7 | 6 |
| 43 | Mortality Among Hospitalized Individuals With Systemic Lupus Erythematosus in the US Between 2006 and 2016. <i>Arthritis Care and Research</i> , 2021 , 73, 1444-1450 | 4.7 | 5 |
| 42 | Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , 2020 , 7, S85-S88 | 1.7 | 5 |
| 41 | COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.. <i>Lancet Rheumatology</i> , 2022 , | 14.2 | 4 |
| 40 | Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate. <i>PLoS ONE</i> , 2016 , 11, e0168369 | 3.7 | 4 |
| 39 | Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2021 , | 8.1 | 4 |
| 38 | Rheumatology Informatics System for Effectiveness (RISE) Practices See Significant Gains in Rheumatoid Arthritis Quality Measures. <i>Arthritis Care and Research</i> , 2020 , | 4.7 | 4 |
| 37 | Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with | 2.4 | 4 |
| 36 | Quality improvement initiatives in rheumatology: an integrative review of the last 5 years. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 98-108 | 5.3 | 4 |
| 35 | Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study. <i>Arthritis Care and Research</i> , 2020 , 72, 283-291 | 4.7 | 4 |
| 34 | Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: Clinical course of COVID-19 in patients with rheumatic disease: a multi-center study of 100 patients with rheumatoid arthritis | 2.4 | 4 |
| 33 | Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019 , 45, 348-357 | 1.4 | 3 |
| 32 | Underestimation of the reliability of codes for rheumatoid arthritis within administrative data: comment on the article by Ng et al. <i>Arthritis Care and Research</i> , 2013 , 65, 835-6 | 4.7 | 3 |
| 31 | Use of Quality Measures to Identify Disparities in Health Care for Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2020 , 46, 623-638 | 2.4 | 3 |
| 30 | Treatment of Sarcoidosis in U.S. Rheumatology Practices: Data from ACRQ Rheumatology Informatics System for Effectiveness (RISE) Registry. <i>Arthritis Care and Research</i> , 2020 , | 4.7 | 3 |
| 29 | Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures. <i>Communications Biology</i> , 2021 , 4, 488 | 6.7 | 3 |
| 28 | Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , 2021 , 232, 49-59 | 11 | 3 |

| | | | |
|----|---|------|---|
| 27 | Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2021 , 4, e2119400 | 10.4 | 3 |
| 26 | Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks. <i>Annals of the Rheumatic Diseases</i> , 2021 , | 2.4 | 3 |
| 25 | COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2021 , | 4.1 | 3 |
| 24 | Scleroderma and Pelvic Organ Prolapse: A Multidisciplinary Approach to Patient Care and Surgical Planning. <i>Journal of Gynecologic Surgery</i> , 2017 , 33, 198-201 | 0.4 | 2 |
| 23 | Improving Patient Safety in Public Hospitals: Developing Standard Measures to Track Medical Errors and Process Breakdowns. <i>Journal of Patient Safety</i> , 2021 , 17, e773-e790 | 1.9 | 2 |
| 22 | Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry | | 2 |
| 21 | Race, Ethnicity and Disparities in Rheumatology Educational Materials. <i>Arthritis Care and Research</i> , 2021 , | 4.7 | 2 |
| 20 | Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Health Care Settings. <i>Arthritis Care and Research</i> , 2020 , 72, 888-896 | 4.7 | 2 |
| 19 | Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021 , 41, 1755-1761 | 3.6 | 2 |
| 18 | Factors Associated With Hospitalization and Death After COVID-19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data. <i>ACR Open Rheumatology</i> , 2021 , 3, 796-803 | 3.5 | 2 |
| 17 | High Disease Severity Among Asians in a US Multiethnic Cohort of Individuals with Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , | 4.7 | 2 |
| 16 | Reweighting to address nonparticipation and missing data bias in a longitudinal electronic health record study. <i>Annals of Epidemiology</i> , 2020 , 50, 48-51.e2 | 6.4 | 1 |
| 15 | The racial/ethnic and sociocultural aspects of the pandemic in rheumatology. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101665 | 5.3 | 1 |
| 14 | The Development of the Rheumatology Informatics System for Effectiveness Learning Collaborative for Improving Patient-Reported Outcome Collection and Patient-Centered Communication in Adult Rheumatology. <i>ACR Open Rheumatology</i> , 2021 , 3, 690-698 | 3.5 | 1 |
| 13 | Using Process Improvement and Systems Redesign to Improve Rheumatology Care Quality in a Safety Net Clinic. <i>Journal of Rheumatology</i> , 2020 , 47, 1712-1720 | 4.1 | 1 |
| 12 | Further Lessons in Pneumocystis Pneumonia Prophylaxis. <i>JAMA Internal Medicine</i> , 2018 , 178, 1565-1566 | 11.5 | 1 |
| 11 | Accurate Measurement In California Safety-Net Health Systems Has Gaps And Barriers. <i>Health Affairs</i> , 2018 , 37, 1760-1769 | 7 | 1 |
| 10 | SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.. <i>RMD Open</i> , 2022 , 8, | 5.9 | 1 |

| | | | |
|---|--|------|---|
| 9 | The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatology Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study. <i>JMIR Medical Informatics</i> , 2021 , 9, e31186 | 3.6 | o |
| 8 | The impact of smoking on disease measures in rheumatoid arthritis: the need for appropriate adjustment of time-varying confounding. <i>Rheumatology International</i> , 2018 , 38, 313-314 | 3.6 | o |
| 7 | Epidemiology and treatment of Behçet disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. <i>Arthritis Research and Therapy</i> , 2021 , 23, 224 | 5.7 | o |
| 6 | The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey.. <i>Rheumatology Advances in Practice</i> , 2022 , 6, rkac001 | 1.1 | o |
| 5 | Using medicare data to understand health care value--reply. <i>JAMA Internal Medicine</i> , 2015 , 175, 462-3 | 11.5 | |
| 4 | Shifting knowledge and attitudes about biosimilars among rheumatologists. <i>Rheumatology</i> , 2021 , 60, 492-493 | 3.9 | |
| 3 | Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Rosenbaum. <i>Annals of the Rheumatic Diseases</i> , 2021 , | 2.4 | |
| 2 | Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2021 , | 2.4 | |
| 1 | Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks. <i>Annals of the Rheumatic Diseases</i> , 2021 , | 2.4 | |